What is the clinical evidence from this study?

Study design: Editorial. Intervention: In silico modeling vs. Animal testing.

What question did this study set out to answer?

The aim is to highlight emerging in silico approaches that reduce reliance on animal testing in drug discovery.

June 25, 2026International Journal of Health & Allied SciencesOpen Access

In silico alternatives to animal testing: Emerging trends in drug discovery

View Full Paper

Ask AI

Bookmark

Key result

In silico modeling shows promise for drug discovery but cannot yet fully replace animal models.

Why the study?

Increasing ethical considerations have driven demand across diverse industrial sectors for affordable, reliable, and robust protocols that can reduce or replace animal testing.

Design

Editorial

Authors

SPShashanka K. PrasadJSS Academy of Higher Education and Research PVPrashant M. VishwanathJSS Academy of Higher Education and Research

Discussion

Member takes

Implication

Animal findings require human validation before any clinical consideration; leaves open translational value for ethical testing alternatives.

Key Points

The aim is to highlight emerging in silico approaches that reduce reliance on animal testing in drug discovery.
Discussed various in silico methods including QSAR, molecular docking, and computational toxicology.
Reviewed the effectiveness of in silico models in predicting drug responses compared to animal models.
Explored the challenges and advancements in computational simulations and AI regarding human physiological complexity.
In silico models demonstrated higher accuracy in predicting clinical responses than traditional animal testing.
Methods such as QSAR and molecular docking proved effective in drug optimization and toxicity prediction.
Ongoing developments in mathematical modeling are required for broader acceptance of in silico techniques.

PICO

Intervention / Comparator

In silico modeling vs Animal testing

This editorial highlights the growing importance of in silico modeling as an ethical, cost-effective alternative to animal testing in drug discovery, while acknowledging its current limitations.

Limitations

These methods are still evolving and have yet to achieve universal adoption, pending the establishment of globally accepted benchmarks.
The capabilities of artificial intelligence and computational simulations remain limited in replicating the full complexity of human physiological processes.
The 'similarity paradox' where structurally similar molecules exhibit differing biological activities
Methods are still evolving and lack globally accepted benchmarks
Limited in replicating the full complexity of human physiological processes

Cite This Study

Prasad et al. (2025) reported an editorial. In silico modeling vs. Animal testing was evaluated. In silico modeling offers a promising alternative to animal testing in drug discovery, though further advancements are needed before computational methods can fully replace animal models.

synapsesocial.com/papers/6a3d91e2408ebb922448b1cd https://doi.org/10.4103/ijhas.ijhas_147_25

View Full Paper

Ask AI

Bookmark

June 25, 2026International Journal of Health & Allied SciencesOpen Access

In silico alternatives to animal testing: Emerging trends in drug discovery

View Full Paper

Ask AI

Bookmark

Key result

In silico modeling shows promise for drug discovery but cannot yet fully replace animal models.

Why the study?

Increasing ethical considerations have driven demand across diverse industrial sectors for affordable, reliable, and robust protocols that can reduce or replace animal testing.

Design

Editorial

Authors

SPShashanka K. PrasadJSS Academy of Higher Education and Research PVPrashant M. VishwanathJSS Academy of Higher Education and Research

Discussion

Member takes

Implication

Animal findings require human validation before any clinical consideration; leaves open translational value for ethical testing alternatives.

Key Points

The aim is to highlight emerging in silico approaches that reduce reliance on animal testing in drug discovery.
Discussed various in silico methods including QSAR, molecular docking, and computational toxicology.
Reviewed the effectiveness of in silico models in predicting drug responses compared to animal models.
Explored the challenges and advancements in computational simulations and AI regarding human physiological complexity.
In silico models demonstrated higher accuracy in predicting clinical responses than traditional animal testing.
Methods such as QSAR and molecular docking proved effective in drug optimization and toxicity prediction.
Ongoing developments in mathematical modeling are required for broader acceptance of in silico techniques.

PICO

Intervention / Comparator

In silico modeling vs Animal testing

This editorial highlights the growing importance of in silico modeling as an ethical, cost-effective alternative to animal testing in drug discovery, while acknowledging its current limitations.

Limitations

These methods are still evolving and have yet to achieve universal adoption, pending the establishment of globally accepted benchmarks.
The capabilities of artificial intelligence and computational simulations remain limited in replicating the full complexity of human physiological processes.
The 'similarity paradox' where structurally similar molecules exhibit differing biological activities
Methods are still evolving and lack globally accepted benchmarks
Limited in replicating the full complexity of human physiological processes

Cite This Study

synapsesocial.com/papers/6a3d91e2408ebb922448b1cd https://doi.org/10.4103/ijhas.ijhas_147_25

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark